TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02083263

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilevel
Description: 3 months

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PEP mask
Description: 3 months
Study: NCT02330263

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: carbohydrate beverage
Description: 400ml of 12.8 g/100 ml carbohydrate beverage
Study: NCT03380481

Intervention type: OTHER
Intervention: observational only-no intervention
Description: Observational only and no predesigned interventions in this study.
Study: NCT00919490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: Tablet, see arms for interventional description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: Tablet, see arms for interventional description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: Tablet, see arms for interventional description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: Tablet, see arms for interventional description

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, see arms for interventional description.
Study: NCT01803737

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Behavioral Weight Loss Intervention (SBWL)
Description: Included changing eating behaviors, increasing physical activity, and attending regular group weight loss meetings.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Campaign Intervention (CI)
Description: Included changing eating behaviors and increasing physical activity, however participants will not attend regular meetings. Instead they will attend two weekly meetings at weeks 0 and 12. During the weeks they are not scheduled to attend in-person weekly meetings (weeks 1-11), they will receive education materials via e-mail. They will also have the opportunity to earn points towards prizes by reporting diet and physical activity behaviors, and body weight via e-mail.
Study: NCT03091491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 1 mg/kg administered every 6 weeks as a 30 min IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3 mg/kg administered every 2 weeks as a 30 min IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3 mg/kg administered every 2 weeks as a 30 min IV infusion
Study: NCT00718081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral sufentanil
Description: Oral dosage of sufentanil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral dosage of placebo
Study: NCT04330326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metabolic Cofactor Supplementation
Description: Subjects in active treatment will receive dietary supplementation with N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside, and serine, administered as a mixture. Half dosage of the co-factors will be given for two weeks (one dose taken just after dinner), and full dosage for 8 weeks (two equal doses taken just after breakfast and dinner).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sorbitol
Description: As placebo, sorbitol (5 g) flavored with strawberry aroma and coloring agent will be given. Sorbitol is widely used due to its solubility in water. It's approved by the U.S. Food and Drug Administration (FDA).
Study: NCT02394145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Patients with normal kidney function and ESRD on hemodialysis will be treated by ticagrelor 90mg twice a day for 14 days. After then, platelet reactivity will be assessed by light aggregometry and VerifyNow assay.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Patients with normal kidney function and ESRD on hemodialysis will be treated by ticagrelor 90mg twice a day for 14 days. After then, platelet reactivity will be assessed by light aggregometry and VerifyNow assay.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Patients with normal kidney function and ESRD on hemodialysis will be treated by clopidogrel 75mg or 150mg once a day for 14 days. After then, platelet reactivity will be assessed by light aggregometry and VerifyNow assay.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Patients with normal kidney function and ESRD on hemodialysis will be treated by clopidogrel 75mg or 150mg once a day for 14 days. After then, platelet reactivity will be assessed by light aggregometry and VerifyNow assay.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Patients with normal kidney function and ESRD on hemodialysis will be treated by clopidogrel 75mg or 150mg once a day for 14 days. After then, platelet reactivity will be assessed by light aggregometry and VerifyNow assay.
Study: NCT00357032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belinostat
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00244842

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: voclosporin
Description: voclosporin 0.2, 0.3, or 0.4 mg/kg po BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: voclosporin
Description: voclosporin 0.2, 0.3, or 0.4 mg/kg po BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: voclosporin
Description: voclosporin 0.2, 0.3, or 0.4 mg/kg po BID
Study: NCT03929055

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Physiological assesment
Description: 1. Arterial blood gas analysis.~2. esophageal pressure variation during inspiration and expiration~3. Arterial blood pressure, central venous pressure (CVP), heart rate.~4. diaphragmatic contraction detected by ultrasound

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Physiological assesment
Description: 1. Arterial blood gas analysis.~2. esophageal pressure variation during inspiration and expiration~3. Arterial blood pressure, central venous pressure (CVP), heart rate.~4. diaphragmatic contraction detected by ultrasound
Study: NCT00244842

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03830177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natural Treatment
Description: The participant will be given the treatment, which contains all natural ingredients, and a kit of all necessary materials to take home with them, which will include a set of instructions. The kit will contain the instruction handout and their treatment. They will be instructed to apply the treatment to their scalp, wait seven minutes, and then rinse their scalp. They will perform this entire procedure once per day for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natural Treatment
Description: The participant will be given the treatment, which contains all natural ingredients, and a kit of all necessary materials to take home with them, which will include a set of instructions. The kit will contain the instruction handout and their treatment. They will be instructed to apply the treatment to their scalp, wait seven minutes, and then rinse their scalp. They will perform this entire procedure once per day for 14 days.
Study: NCT00947050

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dynamic physical exercise
Description: dynamic supine bicycle exercise for 6 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dynamic physical exercise
Description: dynamic supine bicycle exercise for 6 minutes
Study: NCT01931176

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN2Δ30-7169 vaccine
Description: Administered at a dose of 10\^3 plaque-forming units (PFU); delivered by subcutaneous injection in the deltoid region of the upper arm

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Delivered by subcutaneous injection in the deltoid region of the upper arm
Study: NCT01403272

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DermaTherapy® Linen and underpads.
Description: DermaTherapy® Linen is a 100% synthetic silk-like fabric technology designed to provide a cleaner, drier and smoother surface between the skin and support systems for a healthy micro-climate.~Subjects in the DermaTherapy® Linen Group are compared to subjects receiving usual care - bed linen made of cotton-blend fabrics.
Study: NCT03042702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kevetrin
Description: Kevetrin dose to associated cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kevetrin
Description: Kevetrin dose to associated cohort
Study: NCT03849027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxyflurane
Description: Inhaled methoxyflurane will be administered using the disposable field inhaler device (Penthrop®) according to the recommended dosing schedule.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: The sham inhaler will have one droplet of methoxyflurane applied to the outer surface, but no drug in the vaporization chamber to give off the prominent odour with no analgesic effect, partially blinding the participants to the test.
Study: NCT02274701

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Holistic Needs Assessment
Description: An assessment completed by the patient in cancer care. It is recommended that this assessment is completed at key points in the care pathway, such as at diagnosis, post treatment and beginning of end of life care. The aim of this assessment is to allow the patient to discuss their most important needs as identified by them. The clinician will take any appropriate action. This may range from listening to the patient to referring to another member of the multi-disciplinary team.
Study: NCT01124630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-1008
Description: CS-1008 will be administered IV each week. The initial/loading dose (6 mg/kg) will be administered Day 1 of Cycle 1. Maintenance doses of 2 mg/kg will be administered weekly thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: The FOLFIRI regimen will be administered IV at Weeks 1 and 3 of each 4 week cycle, and it will begin at Week 1 of Cycle 1. It will comprise irinotecan, 180 mg/m2 IV infusion over 30 to 120 minutes; leucovorin, 400 mg/m2 IV infusion to match the duration of the irinotecan infusion; and 5-FU, 400 mg/m2 (bolus) followed by 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46 to 48 hours continuous infusion).
Study: NCT01992159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Administered by subcutaneous injection
Study: NCT04322344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escin
Description: treatment with escin or escinate sodium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escin
Description: treatment with escin or escinate sodium

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: standard therapy
Description: antiviral drugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard therapy
Description: antiviral drugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard therapy
Description: antiviral drugs
Study: NCT00507117

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lunesta
Description: Lunesta 3mg prior to PSG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo control
Description: matching placebo
Study: NCT02623647

Intervention type: RADIATION
Group type: OTHER
Intervention: stereotactic body radiotherapy SBRT
Description: 40 Gy in 3 fractions to the prostate gland delivered with stereotactic body radiotherapy
Study: NCT02586350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo p.o. qd
Study: NCT03896594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL237
Description: Experimental

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL237
Description: Experimental

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL237
Description: Experimental

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: placebo with same properties except for active ingredient

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: placebo with same properties except for active ingredient

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: placebo with same properties except for active ingredient
Study: NCT01306838

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MicroLipid and fish oil
Description: Infants in treatment arm will receive the same nutrition support as control group before they tolerate enteral feeding at 20 ml/kg/day. Then they will receive study oils when feeds reach 30 ml/kg/day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: Routine care
Study: NCT04272216

Intervention type: DEVICE
Intervention: Treatment with HydroPearl via radial access
Description: This is an observational study collecting data on patients who are already being treated with HydroPearl on-label per standard of care.
Study: NCT03997019

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: opioid analgesia
Description: opioid analgesia will be used with general anaesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESP block
Description: ultrasound guided ESP Block before anaesthesia induction
Study: NCT02451163

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: wheat polysaccharides
Description: Consumed once daily for 12 weeks.
Study: NCT01992159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Administered by subcutaneous injection
Study: NCT00810797

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: One year after completion of study treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies
Study: NCT02214979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/Ramipril
Description: fixed dose combination tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril tablet
Study: NCT01269567

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laying and management of the drain (strictly randomized arm with drainage)
Description: At the end of intervention, the surgeon will position an aspiration drain in order to permit a postoperative pelvic drainage. The drain will be positioned forward sacrum, behind anastomosis. The drain will be leaved in place between 3 and 5 days. The criteria of drain ablation are the absence of haemorrhagic liquid and/or un daily debit \< 100ml. Nursing care will be daily with change of bottle for collect pelvic serosity, accounting of quantity of collected liquid and realization of a dried bandage through contact with penetration of the drain.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No pelvic drainage
Description: no aspiration drain at the end of intervention
Study: NCT03527901

Intervention type: DIAGNOSTIC_TEST
Intervention: GCF collection with aMMP-8 chair side test

Intervention type: DIAGNOSTIC_TEST
Intervention: GCF collection with aMMP-8 chair side test

Intervention type: DIAGNOSTIC_TEST
Intervention: GCF collection with aMMP-8 chair side test

Intervention type: DIAGNOSTIC_TEST
Intervention: GCF collection with aMMP-8 chair side test

Intervention type: DIAGNOSTIC_TEST
Intervention: GCF collection with aMMP-8 chair side test

Intervention type: OTHER
Intervention: Saliva collection

Intervention type: OTHER
Intervention: Saliva collection

Intervention type: OTHER
Intervention: Saliva collection

Intervention type: OTHER
Intervention: Saliva collection
Study: NCT02451163

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: maltodextrin
Description: Consumed once daily for 12 weeks.
Study: NCT03527901

Intervention type: OTHER
Intervention: Saliva collection
Study: NCT03585556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal anti-VEGF
Description: Intravitreal injection of anti-VEGF at Day 0 then monthly as needed

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravitreal AAVCAGsCD59
Description: An intravitreal injection of AAVCAGsCD59 will occur at Day 7 once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral prednisolone
Description: A 7 day tapering dose of oral prednisone will be taken at Day 30 by all patients
Study: NCT03671954

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Strengthening Exercises
Description: The intervention group will perform unsupervised home strengthening exercises for the hip abductors in addition to standard physical therapy, while the control group will receive standard physical therapy alone.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physical Therapy
Description: Physician determined standard of care for individual TKA patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Physical Therapy
Description: Physician determined standard of care for individual TKA patients.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative Assessments
Description: Assessments will include:~* TUG (timed up and go test) \>12 sec indicates increased fall risk~* Tandem balance test \< 10 sec indicates increased fall risk~* Sit to Stand test (age based norms)~* Knee Range Of Motion (ROM)~* Quadriceps and hamstring strength (MMT or hand held dynamometer)~* Lower Extremity Functional Score (LEFS questionnaire)
Study: NCT00979147

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TKA surgery with modular polished tibial baseplate/XLK design
Description: TKA surgery with modular polished tibial baseplate/XLK design

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TKA surgery with the nonmodular APT/GVF design
Description: TKA surgery with the nonmodular APT/GVF design

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: P.F.C.® Sigma Knee System
Description: P.F.C.® Sigma Knee System with modular XLK poly

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: P.F.C.® Sigma Knee System
Description: P.F.C. ® Sigma Knee System with an all-poly GVF tibia
Study: NCT02180321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: 10mg/kg of tranexamic acid loading infusion for 15 min from beginning of the surgery, then continuous infusion throughout the surgery for 5mg/kg/hr

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal saline
Description: 10mg/kg of normal saline loading infusion for 15 min from beginning of the surgery, then continuous infusion throughout the surgery for 5mg/kg/hr
Study: NCT03776552

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rapid weight loss (RWL) program
Description: 16-week rapid weight loss (RWL) program (8-week low energy diet (LED) followed by 8-week gradual increased energy intake) and a subsequent 36-week weight-maintenance follow-up

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gradual weight loss (GWL) program
Description: 16-week gradual weight loss (GWL) program (moderate calorie restriction) and a subsequent 36-week weight-maintenance follow-up
Study: NCT02491099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Afatinib, 40 mg orally once daily on a 21 day cycle for the first 12 weeks, then every 28 days for subsequent cycles until progression
Study: NCT03328026

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SV-BR-1-GM
Description: SV-BR-1-GM inoculation intradermally at 4 sites.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SV-BR-1-GM
Description: SV-BR-1-GM inoculation intradermally at 4 sites.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose cyclophosphamide
Description: Pretreatment with low dose cyclophosphamide 2-3 days prior to SV-BR-1-GM inoculation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose cyclophosphamide
Description: Pretreatment with low dose cyclophosphamide 2-3 days prior to SV-BR-1-GM inoculation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Inoculation
Description: Post-inoculation low dose Interferon into the vaccination sites \~2 days after SV-BR-1-GM inoculation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Inoculation
Description: Post-inoculation low dose Interferon into the vaccination sites \~2 days after SV-BR-1-GM inoculation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: retifanlimab
Description: retifanlimab 375mg administered as an intravenous infusion over 30-60 minutes every 3 weeks per randomization
Study: NCT03929055

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Physiological assesment
Description: 1. Arterial blood gas analysis.~2. esophageal pressure variation during inspiration and expiration~3. Arterial blood pressure, central venous pressure (CVP), heart rate.~4. diaphragmatic contraction detected by ultrasound
Study: NCT01260324

Intervention type: OTHER
Intervention: No intervention given in this observational study
Description: No intervention given in this observational study

Intervention type: OTHER
Intervention: No intervention given in this observational study
Description: No intervention given in this observational study
Study: NCT03309111

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISB 1342
Description: ISB-1342 is CD38 x CD3 BEAT® 1.0 bispecific antibody. ISB 1342 is administered by intravenous (IV) infusion or subcutaneous injection (SC)
Study: NCT01163565

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ligasure Device
Description: Ligasure device used to seal blood vessels during left or right side of a total thyroidectomy. Traditional method of hand ties/clips on contralateral side.
Study: NCT01529112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lenvatinib matched placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BSC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BSC
Study: NCT00144508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRA (Tocilizumab)
Description: 8mg /kg /4week for 52 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: current treatment
Description: continue current treatment